We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA’s enormous treasure trove of information is a distinguishing asset and perhaps a big barrier to entry for competitors. The company has a huge collection of healthcare information that encompasses more than one billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media.
IQVIA’s addressable market, with a size of more than $300 billion, consists of outsourced research and development, real-world evidence and connected health, and technology-enabled clinical and commercial operation markets. The company aims to expand into these markets by innovating and improving its offerings using its information, advanced analytics, transformative technology and significant domain expertise.
IQVIA’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering a positive average earnings surprise of 2.2%.
Zacks Rank and Stocks to Consider
IQVIA currently carries a Zacks Rank #3 (Hold). Investors interested in the Zacks Business Services sector can consider the following better-ranked stocks.
The company has an impressive earnings surprise history, beating the consensus mark in all the trailing four quarters, with an average surprise of 34.5%.
Maximus (MMS - Free Report) : MMS also sports a Zacks Rank of 1 at present and has a VGM Score of B.
The company has an impressive earnings surprise history, beating the Zacks Consensus Estimate in three of the trailing four quarters and missing once, the average surprise being 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA (IQV) Stock Gains 10% in Three Months: Here's How
IQVIA Holdings Inc.’s (IQV - Free Report) shares have had an impressive run in the past three months.
The stock has gained 9.9% compared with the 9.8% growth of the industry it belongs to and the 7.5% rally of the Zacks S&P 500 composite.
IQVIA Holdings Inc. Price
IQVIA Holdings Inc. price | IQVIA Holdings Inc. Quote
Reasons for the Upside
IQVIA’s enormous treasure trove of information is a distinguishing asset and perhaps a big barrier to entry for competitors. The company has a huge collection of healthcare information that encompasses more than one billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media.
IQVIA’s addressable market, with a size of more than $300 billion, consists of outsourced research and development, real-world evidence and connected health, and technology-enabled clinical and commercial operation markets. The company aims to expand into these markets by innovating and improving its offerings using its information, advanced analytics, transformative technology and significant domain expertise.
IQVIA’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering a positive average earnings surprise of 2.2%.
Zacks Rank and Stocks to Consider
IQVIA currently carries a Zacks Rank #3 (Hold). Investors interested in the Zacks Business Services sector can consider the following better-ranked stocks.
IBEX Limited (IBEX - Free Report) : IBEX currently sports a Zacks Rank #1 (Strong Buy) and has a VGM Score of A. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company has an impressive earnings surprise history, beating the consensus mark in all the trailing four quarters, with an average surprise of 34.5%.
Maximus (MMS - Free Report) : MMS also sports a Zacks Rank of 1 at present and has a VGM Score of B.
The company has an impressive earnings surprise history, beating the Zacks Consensus Estimate in three of the trailing four quarters and missing once, the average surprise being 9.6%.